Association Between IL-17 and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Figures & data

Table 1 Characterstics of the Included Studies

Study	Year	Country	Sample Size	Age				Sex Male/Female				Smoking Status	Reversibility Test	FEV1%				FEV1%FVC%				NOS
				Case		Control		Case		Control				Case		Control		Case		Control
				AE	S	HS	HNS	AE	S	HS	HNS			AE	S	HS	HNS	AE	S	HS	HNS
Nailga kubysheva	2020	Russia	79	NR	63.1±9.6	NR		NR	50/8	NR		Current-smokers	Yes	55.3±21.2		NR		NR	50.5±13.0	NR		6
CHENQZNGYUN	2019	China	120	60.76±9.85	60.84±10.94	61.03±10.53		19/17	26/24	20/20		EX-smokers	NO	NR		NR		NR		NR		6
LiWei	2018	China	165	67±7.75		NR		49/32		NR		EX-smokers	NR	NR		NR		NR		NR		6
Shenghua Jiang	2018	China	105	NR	<70 (33) 44%	<70 (16) 53.3%		NR	NR	NR		Current-smokers	NR	NR		NR		NR		NR
					≥70 (39) 56%	≥70 (14) 46.7%		NR	47/28	15/15		NR	NR							NR		6
Q-Z	2018	China	105	50.47±8.54	50.65±8.19	50.53±8.25		23/19	15/13	21/14		EX-smokers	NO	NR		NR		NR		NR		6
YongZou	2017	China	160	63.9±9.7	62.8±10.8	63.4±8.8		39/21	42/18	28/12		EX-smokers	Yes	NR	52.3±6.5	84.8±4.3		NR	55.0±10.1	84.8±4.3		5
HuayingWang	2015	China	131	68±7	66±7	67±10	64±8	28/5	26/6	32/3	18/13	EX-smokers	NR	36.4±7.2	53.4±8.8	98.3±7.7	103.6±7.3	26.7±3.2	43.8±4.4	81.6±5.8	82.3±6.1	5
HaijunLi	2015	China	63	56.75±10.70		53.43±7.72	35.57±9.73	20/1		20/1	20/1	EX-smokers	NR	52.44±21.83		113.54±14.68	109.48±18.64	49.45±13.03		80.16±5.40	80.75±7.92	6
XiangNanLi	2015	China	108	65±8	67±5	62±7	NR	NR		NR		Current-smokers	NR	35±3.22	43±7.14	110±15.09	NR	41±5.12	59±8.43	89±4.25	NR	6
Lizhang	2013	China	139	62.01±2.74	60.71±2.81	60.2±2.1	60.3±1.7	19/6	17/6	17/6	17/5	Current-smokers	NR	35.13±8.57	72.9±12.44	92.5±4.4	93.4±4.3	52.73±8.87	66.06±9.70	82.8±6.8	83.2±6.7	5

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1%, Percent forced expiratory volume in one second; FVC, Forced vital capacity NOS, Newcastle-Ottawa Quality Assessment Scale; NR, not recorded.

Figure 1 Study selection process: PRISMA flow diagram identifying studies included in the meta-analysis.

Notes: PRISMA figure adapted from Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Creative Commons.³⁴

Abbreviation: PRISMA, Preferred reporting Items for systematic reviews and Meta-analyses.

Figure 2 Forest plot of the serum IL-17 level between SCOPD and control patients.

Abbreviations: SCOPD, stable chronic obstructive pulmonary disease; AECOPD, acute exacerbation chronic obstructive pulmonary disease; SMD, standard mean difference.

Figure 3 Forest plot of the serum IL-17 level between AECOPD and SCOPD patients.

Abbreviations: SCOPD, stable chronic obstructive pulmonary disease; AECOPD, acute exacerbation chronic obstructive pulmonary disease; SMD, standard mean difference.

Figure 4 Forest plot of the sputum IL-17 level between COPD and control patients.

Abbreviations: SCOPD, stable chronic obstructive pulmonary disease; AECOPD, acute exacerbation chronic obstructive pulmonary disease; SMD, standard mean difference.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71

 PubMed Web of Science ®Google Scholar